I
Intellia Therapeutics
Developing Curative CRISPR-Based Medicines
Cambridge, MA
600+
About Intellia Therapeutics
Industry:
Gene Editing/Biotechnology
Founded:
2014
Founders:
Jennifer Doudna, Caribou Biosciences spin-out
Status:
Public (NASDAQ: NTLA)
Funding & Growth
Total Raised:
$1.5B+
Valuation:
$2.5B+ market cap
Stage:
Public
Key Investors:
Atlas Venture
Novartis
Regeneron
✓ Pros
- • In vivo gene editing leader
- • Strong clinical pipeline
- • Regeneron partnership
- • Excellent science culture
- • Kendall Square location
✗ Cons
- • Biotech market volatility
- • Intense competition
- • Regulatory risks
- • High pressure environment